Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better (Commentary)

Atypical hemolytic uremic syndrome (HUS) secondary to anti-factor H autoantibodies has a poor prognosis. The study by Sinha et al. of a large cohort of Indian children makes a substantial contribution to improved management of this form of HUS by showing that standardized titration of anti-factor H autoantibodies is applicable worldwide and that early treatment initiation and guidance of maintenance treatment by autoantibody titer monitoring significantly improve outcomes.


 Authors: Chantal Loirat and V?ronique Fr?meaux-Bacchi

Reference: Kidney Int 85: 1019-1022; doi:10.1038/ki.2013.447

Additional Info

  • Language:
  • Contains Audio:
  • Content Type:
  • Source:
  • Year:
  • Members Only:

Read 1009 times

Last modified on Friday, 20 June 2014 09:03

Scroll to Top